Epinephrine Market Size & Share, by Type (Prefilled Syringes, Auto-Injectors, Ampoules & Vials); Application (Cardiac Arrest, Anaphylaxis, Superficial Bleeding, Respiratory Disorders); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4413
  • Published Date: Feb 02, 2023
  • Report Format: PDF, PPT

Companies Dominating the Epinephrine Landscape

top-features-companies
    • Teva Pharmaceuticals Industries Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Amneal Pharmaceuticals, Inc.
    • Adamis Pharmaceuticals Corporation
    • Antares Pharma, Inc.
    • Pfizer Inc.
    • kaleo, Inc.
    • ALK-Abelló A/S
    • Bausch Health Companies Inc.
    • Viatris Inc.
    • Abbott Laboratories 

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Pfizer Inc. announced that it is in coordination with FDA to extend the expiration dates of certain lots of EpiPen 0.3 mg Auto-Injectors after reviewing the stability data. Pfizer works to stabilize the supply of these particular lots of products so that patients feel confident using them.

  • Teva Pharmaceuticals Industries Ltd. announced the accessibility of the FDA-approved generic version of EpiPen Jr 1 (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S. Currently, the product is available in pharmacies nationwide.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4413
  • Published Date: Feb 02, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Upsurge in chronic respiratory disorders, growing occurrence of several types of allergic reactions, escalation in cardiac arrests are some major factors driving the growth of the market.

The market is anticipated to attain a CAGR of 12% over the forecast period, i.e., 2023-2033.

High cost of auto injectors, lack of availability of approved medicines, and inadequate reimbursement in developing nations are estimated to hamper the market growth.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Teva Pharmaceuticals Industries Ltd., Amneal Pharmaceuticals, Inc., Adamis Pharmaceuticals Corporation, Antares Pharma, Inc., Pfizer Inc., kaleo, Inc., Abbott Laboratories, and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, application, distribution channel, and by region.

The anaphylaxis segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying